While weighing the treatment options for these two cancers, although our initial thoughts were to focus on the more aggressive melanoma (BRAF and NRAS wild type), we were motivated to design a therapy regimen that could yield efficacious responses against both cancers. This evidence concerns the gene NRAS and cancer.